Document is current
Any future updates will be listed below
-
Authors
Faridar, Alireza
Eid, Abdulmunaim M.
Thome, Aaron D.
Zhao, Weihua
Beers, David R.
Pascual, Maria B.
Nakawah, Mohammad O.
Roman, Gustavo C.
Davis, Charles S.
Grundman, Michael
Masdeu, Joseph C.
Appel, Stanley H. https://orcid.org/0000-0003-2747-6298
-
Clinical Trials BETA
Clinical trials referenced in this document:
nct05821153 at ClinicalTrials.govDocuments that mention this clinical trial
A phase 1 open-label pilot study of low-dose interleukine-2 immunotherapy in patients with Alzheimer’s disease
https://doi.org/10.1186/s40035-023-00387-5
-
Funding
Funding for this research was provided by:
Alzheimer's Association (PTCG-21-1818034)
- License Information
-
More Information
Article History
Received: 2 August 2023
Accepted: 6 November 2023
First Online: 16 November 2023
Declarations
:
: The study was reviewed and approved by HMRI Institutional Review Board, and all subjects signed an informed consent form.
: Not applicable.
: DRB declares a conflict of interest as a consultant with Implicit Bioscience and Coya Therapeutics, Inc. ADT declares a conflict of interest as a consultant with Coya Therapeutics, Inc. SHA declares a conflict of interest as a consultant with Implicit Bioscience and scientific advisory board chair of Coya Therapeutics, Inc. The remaining authors have no conflict of interest.
